Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva pairs a medical-device-certified mobile app with remote multidisciplinary care teams to provide evidence-based lifestyle and behavioural interventions for weight management and chronic illnesses. The platform’s embedded AI personalises treatment pathways, supports clinicians’ workflow, and maintains consistent quality at scale. Integrated into national reimbursement schemes such as Germany’s DiGA, the UK’s NHS, and Switzerland’s health system, Oviva removes long wait times and geographic barriers for patients. More than 1 million patients have already used the service, and 90+ clinical studies support its long-term efficacy. Unlike competitors such as Kry/Livi, HelloBetter, Omada Health, or Noom, Oviva focuses on reimbursed, weight-related and metabolic care in European public systems. With fresh capital, the company plans to extend its digital programmes to additional chronic indications, including hypertension and type 2 diabetes, to better manage comorbidities. The €200 million Series D provides significant resources for product expansion and deeper market penetration across Europe.

Total raised

$347M

Funding rounds

4

Latest round

Series D

Latest activity

Jan 2026